Doug Snedden has extensive experience in the corporate sector, having been at the helm of global outsourcing and corporate strategy group Accenture (previously named Andersen Consulting). He was appointed to the Chris O’Brien Lifehouse board as Chairman in February 2014.
With 30 years’ experience in health care as a nurse, manager, and senior executive, Eileen Hannagan was appointed Chief Executive Officer of Chris O’Brien Lifehouse in February 2014. Eileen has studied commerce and health administration, and holds a Masters in Business.
With over 20 years experience as a Medical Oncology, Professor Michael Boyer AM was appointed Chief Clinical Officer of Chris O’Brien Lifehouse in 2011. He has extensive experience as a Director and a Clinical Professor.
David Brettell joined the Chris O’Brien Lifehouse board in October 2014 following eleven years as CEO of the Australian Cancer Research Foundation. David has held high level management roles with AMP, ACRF and MS Australia, among other positions.
As the wife of the late Professor Chris O’Brien (AO), Gail has played an instrumental role in supporting her husband’s vision for a world-class, comprehensive cancer facility in Australia. Gail joined the Lifehouse board soon after Chris’ passing in 2009.
Ian Hammond brings considerable finance expertise to his role at Chris O’Brien Lifehouse, with more than 35 years’ experience in the accounting and finance profession. Ian joined the Lifehouse Board in 2015.
Max Moore-Wilton is one of the most prominent names in Australia’s corporate landscape, with a career that includes key roles within the highest levels of the private and public service sector. He was appointed to the Lifehouse Board in 2007.
Robert McMillan lends substantial commercial experience to his role at Lifehouse and is widely regarded for his ability to identify business trends and developments across broad corporate sectors of print and related industries.
A/Prof Brian McCaughan is a renowned cardiothoracic surgeon with a commitment to the management of thoracic malignancies. He is Chairman of the Clinical Excellence Commission and the Agency for Clinical Innovation, and a Clinical Associate Professor at the University of Sydney.